|
C9ORF85 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.92590055014819E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.13379999727914E-08 |
| Normal-vs-Stage2 |
1.008010E-04 |
| Normal-vs-Stage3 |
2.35000019443987E-10 |
| Normal-vs-Stage4 |
3.61110030766554E-10 |
| Stage1-vs-Stage2 |
9.542000E-01 |
| Stage1-vs-Stage3 |
3.796000E-02 |
| Stage1-vs-Stage4 |
6.464600E-03 |
| Stage2-vs-Stage3 |
1.589210E-01 |
| Stage2-vs-Stage4 |
4.034000E-02 |
| Stage3-vs-Stage4 |
2.807400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.3978996566143E-10 |
| Normal-vs-AfricanAmerican |
1.844030E-04 |
| Normal-vs-Asian |
1.1615999999659E-06 |
| Caucasian-vs-AfricanAmerican |
9.579200E-01 |
| Caucasian-vs-Asian |
7.530800E-01 |
| AfricanAmerican-vs-Asian |
7.966400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.75589997886539E-09 |
| Normal-vs-Female |
7.80669973110548E-10 |
| Male-vs-Female |
4.350800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
9.75410000547683E-08 |
| Normal-vs-Age(41-60Yrs) |
2.79269996017462E-09 |
| Normal-vs-Age(61-80Yrs) |
1.41769995742891E-09 |
| Normal-vs-Age(81-100Yrs) |
3.64330000000024E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.222800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.362400E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.016000E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.812180E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.787600E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.240000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.033800E-01 |
| Classical-VS-Follicular |
1.795190E-01 |
| Classical-VS-Other |
5.312200E-01 |
| Classical-VS-Normal |
5.70079539130575E-11 |
| Tall-VS-Follicular |
1.645980E-02 |
| Tall-VS-Other |
3.448400E-01 |
| Tall-VS-Normal |
3.86289999987355E-08 |
| Follicular-VS-Other |
9.777000E-01 |
| Follicular-VS-Normal |
2.401300E-04 |
| Other-VS-Normal |
7.421500E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.96400000040953E-07 |
| Normal-vs-N1 |
9.36750010893661E-10 |
| N0-vs-N1 |
1.523970E-02 |
|
|
